Adagio Medical Holdings, Inc.
(NASDAQ:ADGM) shares are trending overnight after climbing 21.76% to $0.56 in Monday's after-hours session after the company announced the first patient was successfully treated with its next-generation vCLAS Ultra ablation system under the Food and Drug Administration's Expanded Access authorization.
The after-hours gain followed a 21.60% rise during Monday's regular session, with the stock closing at $0.46.
Adagio Medical develops devices designed to treat dangerous abnormal heart rhythms (cardiac arrhythmias) without open-heart surgery.
First Patient Treated Adagio said the first patient was treated with its next-generation vCLAS Ultra Ultra-Low Temperature Ablation (ULTA) system at the Hospital of the University of Pennsylvania.
